UK markets close in 54 minutes
  • FTSE 100

    7,637.79
    +35.94 (+0.47%)
     
  • FTSE 250

    18,357.55
    +258.87 (+1.43%)
     
  • AIM

    728.20
    +3.22 (+0.44%)
     
  • GBP/EUR

    1.1523
    -0.0025 (-0.21%)
     
  • GBP/USD

    1.2188
    -0.0018 (-0.15%)
     
  • Bitcoin GBP

    22,029.07
    +193.60 (+0.89%)
     
  • CMC Crypto 200

    578.05
    -0.71 (-0.12%)
     
  • S&P 500

    4,321.42
    +21.72 (+0.51%)
     
  • DOW

    33,716.41
    +50.07 (+0.15%)
     
  • CRUDE OIL

    90.82
    -0.89 (-0.97%)
     
  • GOLD FUTURES

    1,878.40
    -0.20 (-0.01%)
     
  • NIKKEI 225

    31,857.62
    -14.90 (-0.05%)
     
  • HANG SENG

    17,809.66
    +436.63 (+2.51%)
     
  • DAX

    15,466.10
    +142.60 (+0.93%)
     
  • CAC 40

    7,171.03
    +54.79 (+0.77%)
     

Why Abbott Laboratories Stock Looks Ridiculously Overpriced

Why Abbott Laboratories Stock Looks Ridiculously Overpriced

Abbott Laboratories (NYSE: ABT) has had a volatile couple of years. It benefited from COVID-related tests boosting its sales, but last year it ran into manufacturing issues that affected its baby formula production and hurt sales in its nutritional segment. The business is now getting back to normal, but the problem is that its valuation still needs to come down significantly before it's a worthwhile buy.